TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.

The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRCA1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

[1]  References , 1971 .

[2]  H. Lane,et al.  p70s6k function is essential for G1 progression , 1993, Nature.

[3]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[4]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[5]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[6]  G. Giles,et al.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[7]  F. Couch,et al.  Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. , 1999, Cancer research.

[8]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[9]  J M Trent,et al.  MYB oncogene amplification in hereditary BRCA1 breast cancer. , 2000, Cancer research.

[10]  Marc J. van de Vijver,et al.  Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers , 2000, Nature Genetics.

[11]  F. Couch,et al.  17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. , 2000, Cancer research.

[12]  F. Couch,et al.  Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. , 2001, Cancer research.

[13]  G. Casey,et al.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers , 2001, Molecular pathology : MP.

[14]  G. Casey,et al.  Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Michael L. Bittner,et al.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.